Target Discovery and Validation Reviews and Protocols
Volume 1, Emerging Strategies for Targets and Biomarker Discovery
Target Discovery and Validation
Reviews and Protocols

Volume 1
Emerging Strategies for Targets and Biomarker Discovery

Edited by

Mouldy Sioud
Department of Immunology,
Institute for Cancer Research,
The Norwegian Radium Hospital,
University of Oslo, Oslo, Norway
Target discovery is a field that has existed for several years but is so vibrant today because of the recent progress in our understanding of the molecular mechanisms of many human diseases and the technical advances in target identification and validation. More sophisticated gene profiling technologies, such as DNA microarrays and serial analysis of gene expression, permit rapid identification of lead targets. Moreover, analysis of gene networks in living organisms allows the identification of target genes that operate in defined physiological pathways. With the sequencing of several genomes completed and the rapidly growing gene expression databases, there is now greater impetus than ever before for in silico discovery of therapeutic targets. Also, recent advances in genetic technologies have increased our ability to generate mouse models for human diseases. The implications of these genetically modified animals in drug development are several, including identification of new drug targets, predicting efficacy, and uncovering possible side effects. Together, these recent technical advances should allow researchers to make the most informed choice early and advance the chosen targets toward clinical studies.

Regarding cancers, any difference between a cancer and a normal cell could potentially be exploited as a therapeutic target. The hope is that drugs targeting specific constituents or pathways in cancer cells will provide more effective therapy, either alone or in combination with other currently used anticancer drugs. In addition to drug targets, identifying new target antigens remains as much of a challenge as improving tumor vaccines already in the clinic. New techniques such as SEREX, phage display, proteomics, and reverse immunology have not only yielded a significant number of new tumor antigens, but they have influenced our understanding of the interaction between the immune system and tumor cells. New adjuvants to improve vaccine potency are also being discovered.

Validating potential drug targets is one of the most critical steps in drug discovery. At present, the currently available target identification technologies appear to yield too many targets. Therefore, programs need to focus on defining the targets that are specific and “druggable” with small inhibitors. While true target validation comes only when a selective inhibitor for the chosen target is tested in patients and exhibits efficacy in the appropriate human disease, the appropriate cell culture and animal studies prior to the trial are not only required but should provide crucial information regarding the validity of the chosen tar-
get. Approaches to target validation might involve the use of small interfering RNAs, antisense oligonucleotides, antibodies, or engineered transgenic or knockout mice. Notably, several human diseases such as cancers and autoimmune disorders can be modeled in the mouse, making it an ideal tool to accelerate the validation process of new agents and the assessment of risk and toxicity.

Because of the rapid technical progress in the target discovery and validation field, we decided to divide *Target Discovery and Validation Reviews and Protocols* into two separates books, each describing specific topics. Volume 1, *Emerging Strategies for Targets and Biomarker Discovery*, provides the recent technological advances for the identification of molecular drug targets, biomarkers, and tumor antigens. In addition, it describes the role of knockout mice in functional genomics and target validation, as well as the clinical impact of gene expression profiling on oncology diagnosis, prognosis, and treatment. Volume 2, *Emerging Molecular Targets and Treatment Options*, concentrates on target validation strategies and on efforts to bring agents against specific targets closer to clinical application. We are presenting very up-to-date overviews and protocols by experts in the field. The covered topics will be of interest to researchers, pharmaceutical companies, and clinicians interested in developing or using new therapies. In addition, *Target Discovery and Validation Reviews and Protocols* will assist academic clinicians and students of biology, medicine, or pharmacy to appreciate the progress of the past few years in our understanding of cancer pathogenesis, cell signaling, gene profiling approaches, tumor immunology, tumor immunoediting, and immune tolerance.

I would like to thank the authors for their contributions, Anne Dybwad for critical reading of the manuscripts, and all those involved in the production of *Target Discovery and Validation Reviews and Protocols*. 

*Mouldy Sioud*
## Contents

Preface ........................................................................................................ v
Contributors ................................................................................................ ix
Contents of Volume 2 ............................................................................... xi

1 Main Approaches to Target Discovery and Validation
   *Mouldy Sioud* .......................................................................................... 1

2 Bioinformatics Approaches to Cancer Gene Discovery
   *Ramaswamy Narayanan* ........................................................................ 13

3 Analysis of Gene Networks for Drug Target Discovery and Validation
   *Seiya Imoto, Yoshinori Tamada, Christopher J. Savoie, and Satoru Miyano* .................................................................................. 33

4 Target Discovery and Validation in Pancreatic Cancer
   *Robert M. Beaty, Mads Gronborg, Jonathan R. Pollack, and Anirban Maitra* ...................................................................................... 57

5 Molecular Classification of Breast Tumors: Toward Improved Diagnostics and Treatments
   *Therese Sørlie* ....................................................................................... 91

6 Discovery of Differentially Expressed Genes: Technical Considerations
   *Øystein Røsok and Mouldy Sioud* ..................................................... 115

7 Genome-Wide Screening by Using Small-Interfering RNA-Expression Libraries
   *Sahohime Matsumoto, Makoto Miyagishi, and Kazunari Taira* ........ 131

8 Hammerhead Ribozyme-Based Target Discovery
   *Masayuki Sano and Kazunari Taira* .................................................... 143

9 Production of siRNA and cDNA-Transfected Cell Arrays on Noncoated Chambered Coverglass for High-Content Screening Microscopy in Living Cells
   *Holger Erfle and Rainer Pepperkok* ..................................................... 155
10 Transgenic Animal Models in Biomedical Research
   Louis-Marie Houdebine .......................................................... 163

11 Keratin Transgenic and Knockout Mice: Functional Analysis and Validation of Disease-Causing Mutations
   Preethi Vijayaraj, Goran Söhl, and Thomas M. Magin .......... 203

12 The HUVEC/Matrigel Assay: An In Vivo Assay of Human Angiogenesis Suitable for Drug Validation
   Dag K. Skovseth, Axel M. Küchler, and Guttorm Haraldsen . 253

13 A Murine Model for Studying Hematopoiesis and Immunity in Heart Failure
   Per Ole Iversen and Dag R. Sørensen ................................. 269

14 An Overview of the Immune System and Technical Advances in Tumor Antigen Discovery and Validation
   Mouldy Sioud ....................................................................... 277

15 Potential Target Antigens for Immunotherapy Identified by Serological Expression Cloning (SEREX)
   Dirk Jäger ........................................................................... 319

16 Identification of Tumor Antigens by Using Proteomics
   François Le Naour ................................................................ 327

17 Protein Arrays: A Versatile Toolbox for Target Identification and Monitoring of Patient Immune Responses
   Lina Cekaite, Eivind Hovig, and Mouldy Sioud...................... 335

Index ............................................................................................. 349
Contributors

ROBERT M. BEATY • Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD

LINA Cekaite • Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

HOLGER ERFLE • Cell Biology and Cell Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany

MADS GRONBORG • McKusick–Nathans Institute of Genetic Medicine; Departments of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark

GUTTORM HARALDSEN • Institute of Pathology, Rikshospitalet University Hospital, Oslo, Norway

LOUIS-MARIE HOUDEBINE • Biologie du Developpement et Reproduction, Institut National de la Recherche Agronomique, Paris, France

EIVIND HOVIG • Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

SEIYA IMOTO • Human Genome Centre, Institute of Medical Science, University of Tokyo, Tokyo, Japan

PER OLE IVERSEN • Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

DIRK JÄGER • Medizinische Onkologie, Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Germany

AXEL M. KÜCHLER • Institute of Pathology, Rikshospitalet University Hospital, Oslo, Norway

FRANÇOIS LE NAOUR • INSERM V602, Hôpital Paul Brousse, Villejuif, France

THOMAS M. MAGIN • Institut für Physiologische Chemie, Abteilung für Zellbiochemie, Bonner Forum Biomedizin und LIMES, Universitätsklinikum Bonn, Bonn, Germany

ANIRBAN MAITRA • Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center and McKusick–Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
SAHOHIME MATSUMOTO • Department of Chemistry and Biotechnology, School of Engineering, Tokyo, Japan

MAKOTO MIYAGISHI • Gene Function Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

SATORU MIYANO • Human Genome Centre, Institute of Medical Science, University of Tokyo, Tokyo, Japan

RAMASWAMY NARAYANAN • Center for Molecular Biology and Biotechnology and Department of Biology, Florida Atlantic University, Boca Raton, FL

RAINER PEPPERKOK • Cell Biology and Cell Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany

JONATHAN R. POLLACK • Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center and McKusick–Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

ØYSTEIN ROSOK • Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

MASAYUKI SANO • Gene Function Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

CHRISTOPHER J. SAVOIE • Gene Networks International, Tokyo, Japan

MOULDY SIoud • Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

DAG K. SKOVSETH • Institute of Pathology, Rikshospitalet University Hospital, Oslo, Norway

GORAN SÖHL • Institut für Physiologische Chemie, Abteilung für Zellbiochemie, Bonner Forum Biomedizin and LIMES, Universitätsklinikum Bonn, Bonn, Germany

DAG R. SØRENSEN • Centre of Comparative Medicine, Rikshospitalet University Hospital, Oslo, Norway

THERESI SØRLIE • Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

KAZUNARI TAIRA • Department of Chemistry and Biotechnology, School of Engineering, Tokyo, Japan

YOSHINORI TAMADA • Institute of Statistical Mathematics, Tokyo, Japan

PREETHI VIJAYARAJ • Institut für Physiologische Chemie, Abteilung für Zellbiochemie, Bonner Forum Biomedizin and LIMES, Universitätsklinikum Bonn, Bonn, Germany
Contents of Volume 2:
Emerging Molecular Targets and Treatment Options

1 Druggable Signaling Proteins
*Mouldy Sioud and Marianne Leirdal*

2 DNA Methylation and Histone Modifications in Patients With Cancer: Potential Prognostic and Therapeutic Targets
*Michel Herranz and Manel Esteller*

3 Wnt Signaling as a Therapeutic Target for Cancer
*Andreas Herbst and Frank Thomas Kolligs*

4 The Ng2/Hmp Proteoglycan as a Cancer Therapeutic Target
*Martha Chekenya and Heike Immervoll*

5 Heterotrimeric G Proteins and Disease
*Øyvind Melien*

6 High-Mobility Group Box-1 Isoforms as Potential Therapeutic Targets in Sepsis
*William Parrish and Luis Ulloa*

7 Antisense Oligonucleotides: Target Validation and Development of Systemically Delivered Therapeutic Nanoparticles
*Chuanbo Zhang, Jin Pei, Deepak Kumar, Isamu Sakabe, Howard E. Boudreau, Prafulla C. Gokhale, and Usha N. Kasid*

8 Nucleic Acid-Based Aptamers as Promising Therapeutics in Neoplastic Diseases
*Laura Cerchia and Vittorio de Franciscis*

9 Guidelines for the Selection of Effective Short-Interfering RNA Sequences for Functional Genomics
*Kumiko Ui-Tei, Yuki Naito, and Kaoru Saigo*

10 Suppression of Apoptosis in the Liver by Systemic and Local Delivery of Small-Interfering RNA
*Lars Zender and Stefan Kubicka*

11 Target Validation Using RNA Interference in Solid Tumors
*Seyedhossein Aharinejad, Mouldy Sioud, Trevor Lucas, and Dietmar Abraham*
12 Validation of Telomerase and Survivin as Anticancer Therapeutic Targets Using Ribozymes and Small-Interfering RNAs
   
   Nadia Zaffaroni, Marzia Pennati, and Marco Folini

13 Collagen-Induced Arthritis in Mice: A Major Role for Tumor Necrosis Factor-α
   
   Richard O. Williams

14 Novel Opportunities for Therapeutic Targeting in Systemic Autoimmune Diseases
   
   Meryem Ouarzane and Moncef Zouali

15 Considerations for Target Validation and Industrial Approaches
   
   Carlos R. Plata-Salamán and Sergey E. Ilyin

16 Regulatory RNAs: Future Perspectives in Diagnosis, Prognosis, and Individualized Therapy
   
   Marjorie P. Perron, Vincent Boissonneault, Lise-Andrée Gobeil, Dominique L. Ouellet, and Patrick Provost

17 Treatment Options and Individualized Medicine
   
   Mouldy Sioud and Øyvind Melien